Alexander Mann | Senior Director, Clinical Sciences
Alex Mann has a specific interest in the use of human challenge models to answer key questions around host responses to infection as well as efficacy of treatments and vaccines. Over the last 23 years at hVIVO (formally Retroscreen Virology Ltd.) he has led, managed, designed, and analysed an array of studies using challenge agents such as SARS-Cov-2, RSV, Influenza, and HRV in both healthy subjects and in those with asthma.
WVIC/WAC Day 2 – Nov 30 @ 14:30 – Vaccine and Treatment Efficacy: viral disease, patient illness perception and implications for respiratory viral challenge studies
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.